- Home
- YQ vs AYTU Comparison
YQ vs AYTU Comparison
Compare YQ & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- AYTU
- Stock Information
- Founded
- YQ 2012
- AYTU N/A
- Country
- YQ China
- AYTU United States
- Employees
- YQ N/A
- AYTU N/A
- Industry
- YQ Other Consumer Services
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- AYTU Health Care
- Exchange
- YQ Nasdaq
- AYTU Nasdaq
- Market Cap
- YQ 19.4M
- AYTU 19.7M
- IPO Year
- YQ 2020
- AYTU N/A
- Fundamental
- Price
- YQ $1.97
- AYTU $2.20
- Analyst Decision
- YQ
- AYTU Strong Buy
- Analyst Count
- YQ 0
- AYTU 2
- Target Price
- YQ N/A
- AYTU $10.00
- AVG Volume (30 Days)
- YQ 20.8K
- AYTU 109.6K
- Earning Date
- YQ 09-03-2025
- AYTU 09-25-2025
- Dividend Yield
- YQ N/A
- AYTU N/A
- EPS Growth
- YQ N/A
- AYTU N/A
- EPS
- YQ N/A
- AYTU N/A
- Revenue
- YQ $25,546,613.00
- AYTU $81,659,000.00
- Revenue This Year
- YQ N/A
- AYTU N/A
- Revenue Next Year
- YQ N/A
- AYTU $1.05
- P/E Ratio
- YQ N/A
- AYTU N/A
- Revenue Growth
- YQ N/A
- AYTU 0.41
- 52 Week Low
- YQ $1.26
- AYTU $0.95
- 52 Week High
- YQ $3.19
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- YQ 46.13
- AYTU 43.54
- Support Level
- YQ $1.94
- AYTU $2.15
- Resistance Level
- YQ $2.02
- AYTU $2.28
- Average True Range (ATR)
- YQ 0.07
- AYTU 0.11
- MACD
- YQ 0.01
- AYTU -0.03
- Stochastic Oscillator
- YQ 75.00
- AYTU 16.07
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.